Coagulation System in Peripheral Arterial Disease: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Contributor:
Giuseppe Miceli
,
Maria Grazia Basso
,
Giuliana Rizzo
,
Chiara Pintus
,
Antonino Tuttolomondo

Peripheral artery disease (PAD) is a clinical manifestation of atherosclerotic disease with a large-scale impact on the economy and global health. Histopathological analysis and some clinical studies conducted on atherosclerotic plaques testify to the existence of different types of plaques. Likely, the role of coagulation in each specific type of plaque can be an important determinant in the histopathological composition of atherosclerosis and in its future stability.

  • peripheral artery disease
  • coagulation
  • atherosclerosis

1. Introduction

Peripheral artery disease (PAD) is a clinical manifestation of atherosclerotic disease with a large-scale impact on the economy and global health, affecting over 200 million people worldwide [1]. The term PAD refers to all arterial trees, except for the aorta and coronary arteries, as recently emphasized by Tran et al. [2]. The prevalence of PAD is approximately 12% in the adult population, with males being affected slightly more than females [3]. Even if symptoms and manifestations may be disabling, most patients can present an asymptomatic PAD. Due to the lack of characteristic signs and symptoms, these patients are often under-recognized and undertreated [4].
The goal of identifying the molecular pathways involved in both asymptomatic and symptomatic patients is to prevent the progression and complications of PAD and find subjects with a high risk for cardiovascular disease [5]
In fact, though asymptomatic patients do not have limitations in carrying out daily activities, they present an increased risk for major cardiovascular events [6]. A large international registry of patients found that 5.4% of patients with established PAD had a major cardiovascular event such as cardiovascular death, myocardial infarction, or stroke at one year, and 21% experienced these endpoints or hospitalization for an atherosclerotic event [7][8].
Despite the role played by platelets in the process of atherogenesis being well recognized, evidence has been increasing on the contribution of the coagulation system to the atherosclerosis formation and PAD development [9][10].
In fact, the interaction between the activated platelet and the artery wall is a fundamental process for atherothrombotic disease, but it is also responsible for augmented fibrinogen concentrations, thrombin formation, and fibrin turnover. The role of coagulation proteins in PAD pathogenesis is established not only in acute thrombotic complications but also in the stable stages of the disease, where fibrinogen and thrombin seem to be associated with the clinical severity [11]. The growing evidence concerning the central role of the coagulation cascade in the pathogenesis of PAD is also responsible for important repercussions for the therapeutic approach.
Given the implication of the hemostasis process and coagulative proteins in the pathophysiology of PAD, the use of anticoagulant therapy alone or in combination with antiplatelets has been considered as a potential antithrombotic option for antiplatelets alone.

2. Role of Coagulation in the Formation and Progression of Atherosclerosis

Coagulation is involved in thrombus formation and, therefore, in PAD progression. According to the composition, the thrombi can be categorized into acute or chronic (organized). Thrombus formation is driven by activated platelet and thrombin generation pathways. Acute thrombi are composed of red blood cells, fibrin, and platelets which adhere to the endothelial wall after the disruption of the atheromatic plaque and the exposure of the necrotic core. Chronic thrombus is defined by the presence of capillaries, smooth cells, connective tissue and inflammatory cells. While acute thrombi can be detected indiscriminately in advanced atherosclerotic and non-significant atherosclerotic lesions, chronic thrombi are observed more frequently in non-significant atherosclerotic plaque.
The disruption of an atherosclerotic lesion, exposing thrombogenic material to the blood, is the starting mechanism of the atherothrombotic events leading to plaque progression [12]. Several coagulation proteins have been implicated in proinflammatory conditions and atherosclerosis. The presence of tissue factor (TF) is considered the primary physiologic trigger of the coagulation cascade in atherosclerotic lesions: Wilcox et al. showed that TF was found on the membrane of macrophages and vascular smooth muscle cells, where it co-localizes with factor VII [13]. Furthermore, elevated TF levels have been found in patients with PAD. Abnormal TF levels have been detected mainly in early atherosclerotic lesions compared to stable advanced atherosclerotic plaque, suggesting a procoagulant state, especially in early stages of atherosclerosis, amplified by the reduction of inhibitor pathways of coagulation, as demonstrated by a higher TF/TF pathway inhibitor ratio in patients with early atherosclerosis [14].
Endogenous thrombin and thrombin–antithrombin complex values indicated a procoagulant profile of early atherosclerotic lesions compared to stable advanced atherosclerotic lesions. In subclinical atherosclerotic disease, a relation between TF and an increased carotid intimate media thickness has been documented as a marker of early atherosclerosis [14]. The presence of coagulation components, such as thrombin levels and thrombin/antithrombin complexes, in atherosclerotic lesions suggests the role of these clotting proteins in plaque thrombogenicity. The fact that coagulation proteins are more present in early atherosclerotic lesions compared to advanced atherosclerotic lesions supports an important role for these coagulation factors in the initial development of atherosclerosis rather than an involvement limited to thrombus formation in unstable plaques only [15].
These data might suggest a possible thromboembolic phenomenon in the peripheral arterial occlusion—above all, in infrapopliteal arteries—explaining the relatively lower incidence of chronic limb ischemia compared to PAD prevalence [16].
These data support the evidence of a procoagulant state in patients with peripheral artery disease, whose expression is more evident in the early stages, suggesting that thrombotic complications do not depend on the plaque size.
Furthermore, abnormal levels of thrombin, factor X, TF, and FXII have been detected in circulating blood. The expression of these proteins has also been noticed on the arterial wall, particularly in the early stages. This different expression might be attributed to the different plaque compositions. Indeed, early plaques are composed of inflammatory cells, producing procoagulant proteins, so the expression of coagulation factors in the vascular wall depends not only on the translocation from blood flow but also on the local production by the inflammatory cells. A change in plaque composition might explain why stable advanced atherosclerotic lesions, composed of fibrotic tissue surrounding the necrotic lipidic core, express fewer coagulation factors [17][18].

3. Plaque Composition and Vulnerability: Differences in Coronary and Peripheral Atherosclerotic Disease

The modified AHA classification [19] categorizes atherosclerotic plaques into adaptive intimal thickening (AIT), pathological intimal thickening (PIT), fibroatheroma (FA), and fibrocalcific plaque (FC). AIT is considered the expression of non-significant atherosclerosis, and it also includes atherosclerotic lesions composed of smooth cells without a lipid matrix. PIT refers to plaques with smooth cells and extracellular lipids, while fibrous caps surrounding lesions are classified as FA and calcified plaques are classified as FC; PIT, FA, and FC are classified as significant atherosclerosis.
CAD and PAD might be considered two distinct expressions of the same condition, but, although similar, they present different characteristics that are secondary to the peculiarities of the two vascular districts affected. Many factors, including anatomical features such as vessel size and tortuosity, local shear stress and inflammation on the arterial wall, and the presence of vasa vasorum, are responsible for a different composition of atherosclerotic plaques in coronary and peripheral arteries. In fact, coronary lesions are prevalently constituted from a central lipid-necrotic core composed of cholesterol (LRNC), oxidized LDL, and necrotic foam cells surrounded by a thin fibrotic cap, while the LEAD plaques present more frequently fibroproliferative and calcific lesions, without q lipid core and a prevalent composition of collagen, smooth cells, and calcification [20].
The different plaque composition is responsible for more vulnerability in the coronary than the peripheral arteries. Indeed, plaque stability depends on the percentage of fibrotic and lipidic components; therefore, connective tissue stabilizes atherosclerotic lesions, making complications, such as plaque rupture, less likely [21].
Many studies have analyzed the plaque composition in coronary and peripheral arteries with non-invasive imaging such as Magnetic Resonance, proving that only 25% of patients with LEAD had LRNC lesions, with a higher prevalence in smoking patients [22][23]. LRNC plaques are associated with a higher risk of LEAD complications, defined as a worsening ankle brachial index (ABI) and critical limb ischemia requiring intervention, [22] even if prior studies did not find any significant association between LNRC and ABI decline or lumen stenosis but rather only with local atherosclerotic severity [24].
The risk of complications also depends on the increase in inflammatory cells in the plaques. Recent evidence has demonstrated a major prevalence of macrophages and lymphocytes in the coronary and carotid lesions compared to the femoral plaques, supporting a less inflammatory process in peripheral circulation, as confirmed by a lower uptake of fluorodeoxyglucose in the femoral arteries compared to the carotid arteries in many studies using FDG-PET to determine inflammatory involvement in the atherosclerotic disease [25][26].
Histopathological studies have shown that atherosclerotic disease progression is related to local clotting formation. Some plaque components—in particular, cholesterol compounds—reveal marked thrombogenicity, promoting the activation of the coagulation cascade and the thrombus formation.
Previous studies demonstrated abnormal concentrations of coagulation factors, such as von Willebrand’s factor, fibrinogen, and factor VIIa, as well as increased plasminogen activator inhibitor-1 and tissue-type plasminogen activator antigen in patients with CAD, promoting the hypothesis that an impaired balance between coagulation and fibrinolysis might be involved in coronary atherosclerosis. [27]. These data were confirmed in more recent studies, underlying the possible role of some clotting proteins as biomarkers of CAD. In fact, elevated levels of fibrinogen and soluble fibrin monomer complexes and decreased concentrations of prothrombin were identified in patients with CAD in comparison with healthy controls [28]. As opposed to cardiovascular events, which occur in the case of plaque rupture, peripheral ischemia is often associated with chronic thrombus formation in the absence of atherosclerotic lesions, indicating a possible procoagulant state in PAD. Coagulation plays an essential role in the initial processes leading to plaque formation but also in the growth of the atherosclerotic lesions and the progression of peripheral artery disease, as suggested by the finding of altered levels of coagulation factors in patients affected by PAD [16].

4. Endothelial Disfunction in Chronic Kidney Disease and the Risk of Lower Extremity Atherosclerosis

Patients with kidney disease are more often diagnosed with peripheral atherosclerosis than equivalents without renal dysfunction [29][30][31]. Chronic kidney disease (CKD) and atherosclerosis share the same risk factors (smoking, age, sex, comorbidities such as hypertension, diabetes, and hyperlipidemia) inducing vascular damage. Nevertheless, different studies have demonstrated that kidney dysfunction is associated with a higher risk of peripheral artery disease regardless of the classical risk factors for atherosclerosis [32][33][34][35][36].
There are two main mechanisms responsible for endothelial dysfunction in patients with chronic kidney disease. The first one is the activation of a proinflammatory state: indeed, patients affected by end-stage renal disease (ESRD) show elevated serum concentrations of acute phase proteins, such as C-reactive protein, IL-6, and TNF-alpha, demonstrating the activation of proinflammatory processes in kidney injury [37]. On the other hand, the reduced availability of molecules with vasodilatory action—in particular, nitric oxide (NO) bioavailability—induces the dysregulation of the vascular tone. Confirming these data, recent studies showed impairment in endothelium-dependent vasodilatation in ESRD [38].
Inflammation causes endothelial dysfunction, inducing the expression of adhesion molecules on the vascular wall and increasing the levels of TNF-alpha, which are responsible for the cytotoxic effect on the endothelial cells [39]. As the renal damage progresses, some soluble adhesion molecules, such as ICAM-1, VCAM-1, and MMP, are dismissed from endothelial cells and activate the NfkB pathway, with the final result of reducing the NO levels [40].
Oxidative stress is another mechanism that is decisive for endothelial dysfunction in chronic kidney disease: the interconnection between these two processes comes through increased levels of myeloperoxidase (MPO). Indeed, the activation of neutrophils in inflammatory processes determines the production of MPO, using NO as a substrate, and leads to lipid peroxidation through the generation of diffusible oxidants and oxidized-LDL (ox-LDL), whose levels in CKD are inversely related to endothelial function [41].
Moreover, oxidative stress leads to the production of the AGE (advanced glycation end-products), molecules whose action is to inhibit DDAH, and the degradation enzyme of asymmetric dimethylarginine (ADMA), a competitive inhibitor of L-arginine inducing the inactivation of eNOS (endothelial NO synthase), with a consequently reduced availability of NO [42].
Increased levels of AGE are detected in patients with chronic kidney disease.
In addition, the lower serum concentration of triiodothyronine induced by inflammation is another factor responsible for impaired ADMA levels in ESRD [43].
Other factors cause the lowering of NO availability in CKD patients. Hyperphosphatemia, vitamin D deficit, and FGF23 overexpression contribute to the inactivation of eNOS in renal damage; furthermore, the lower levels of NO in renal dysfunction are also the consequence of the reduced synthesis and transport of the precursor L-arginine [44][45][46][47].
A recent study by Batkoa et al. showed an elevated expression of thrombomodulin (TM) in patients with ESRD [48]. TM is a glycoprotein whose expression has been found on the endothelium covering atherosclerotic plaques and on the macrophages and smooth cells; TM is also released from endothelial cells after vascular damage [49][50]. The increased levels of TM are positively associated with TNFR2 (soluble tumor necrosis factor receptor type 2) and osteopontin (OPN) expression. TNFR2 activation induced by TNFalpha binding has a central role in the clotting pathway beginning, leading to arteriolar thrombosis [51], while osteopontin is a cytokine involved in differentiating smooth muscle cells into an osteogenic phenotype, promoting vascular calcification and the progression of atherosclerotic disease [52][53]. OPN concentrations correlate with medial arterial calcifications, which are associated with a higher risk of cardiovascular and mortality risk in patients with CKD [54]. However, the mechanisms through which OPN and TNFR2 are related to increased levels of TM still need to be clarified.
Finally, increased concentrations of vWF (von Willebrand Factor) have been detected in patients with ESRD, suggesting a correlation between the coagulation system and thrombogenicity in kidney disease [55][56].
The interconnection between chronic kidney disease and endothelial dysfunction led to defining a new life-threatening clinical entity called malnutrition-inflammation-atherosclerosis (MIA) syndrome, in which the three aforementioned mechanisms synergistically concur to increase the cardiovascular risk and set the outcome of ESRD patients [57].
Based on these data, researchers can affirm that endothelial dysfunction in chronic kidney disease results from different processes leading to endothelial damage and dysregulation, which are responsible for accelerated atherosclerosis and a higher incidence of lower extremity atherosclerotic disease in patients with renal impairment.
About a quarter of patients with CKD with eGFR < 60 mL/min/1.73 m2 suffer from peripheral artery disease, representing an independent risk factor for mortality and extended hospitalization, particularly in chronic limb ischemia [58].
The incidence of LEAD (Lower Extremity Atherosclerotic Disease) is higher in proportion with the degree of kidney damage: the risk of LEAD is 1.2–2.5 fold higher in patients with chronic kidney disease G3–G5, and the risk of lower limb complications needing amputation is more frequent in eGFR < 30 mL/min/1.73 m2 in comparison with patients with normal renal function [59][60]. In addition, the risk is higher in patients undergoing dialysis because of the biochemical abnormalities leading to systemic inflammation, hypoalbuminemia, and hyperphosphatemia associated with chronic uremia [61][62].
The demonstration that CKD is a significant risk for LEAD is supported by data coming from a recent meta-analysis evaluating the outcome in patients with renal damage undergoing peripheral artery interventions in comparison with patients not affected by kidney disease: the study showed that target lesion revascularization (TLR), major amputations, and long-term mortality were most frequent in patients with CKD and, in particular, in ESRD, suggesting a pathogenic role of kidney dysfunction in the severity of peripheral atherosclerosis [63].
The data reported can lay the basis for the optimal clinical approach to patients with CKD who need to be evaluated for asymptomatic peripheral artery disease through the measurement of the ankle-brachial-index (ABI) to prevent the progression of lower extremity atherosclerosis and complications, even if ABI might be falsely normal in patients with ESRD and medial arterial calcification such that other diagnostic tools such as exercise ABI, the toe-brachial index, or duplex ultrasonography should be performed.
Lower extremity atherosclerosis in CKD is, therefore, the result of a complex interlacement of multiple processes resulting in vascular damage: for this reason, the management should include the participation of a multidisciplinary team, including a vascular surgeon, a physician, a wound care specialist, and a nephrologist, to perform the best diagnostic and therapeutic assessment of patients with peripheral atherosclerosis and chronic kidney disease.

This entry is adapted from the peer-reviewed paper 10.3390/ijms232314914

References

  1. Fowkes, F.G.; Rudan, D.; Rudan, I.; Aboyans, V.; Denenberg, J.O.; McDermott, M.M.; Norman, P.E.; Sampson, U.K.; Williams, L.J.; Mensah, G.A.; et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: A systematic review and analysis. Lancet 2013, 382, 1329–1340.
  2. Tran, B. Assessment and management of peripheral arterial disease: What every cardiologist should know. Heart 2021, 107, 1835–1843.
  3. Sampson, U.K.; Fowkes, F.G.; McDermott, M.M.; Criqui, M.H.; Aboyans, V.; Norman, P.E.; Forouzanfar, M.H.; Naghavi, M.; Song, Y.; Harrell, F.E., Jr.; et al. Global and regional burden of death and disability from peripheral artery disease: 21 world regions, 1990 to 2010. Glob. Heart 2014, 9, 145–158.
  4. Novo, S. Classification, epidemiology, risk factors, and natural history of peripheral arterial disease. Diabetes Obes. Metab. 2002, 4 (Suppl. S2), S1–S6.
  5. Rooke, T.W.; Hirsch, A.T.; Misra, S.; Sidawy, A.N.; Beckman, J.A.; Findeiss, L.K.; Golzarian, J.; Gornik, H.L.; Halperin, J.L.; Jaff, M.R.; et al. 2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in collaboration with the Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society for Vascular Medicine, and Society for Vascular Surgery. Catheter. Cardiovasc. Interv. 2012, 79, 501–531.
  6. Anderson, J.L.; Halperin, J.L.; Albert, N.M.; Bozkurt, B.; Brindis, R.G.; Curtis, L.H.; DeMets, D.; Guyton, R.A.; Hochman, J.S.; Kovacs, R.J.; et al. Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA guideline recommendations): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013, 127, 1425–1443.
  7. Steg, P.G.; Bhatt, D.L.; Wilson, P.W.; D’Agostino, R., Sr.; Ohman, E.M.; Röther, J.; Liau, C.S.; Hirsch, A.T.; Mas, J.L.; Ikeda, Y.; et al. REACH Registry Investigators. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007, 297, 1197–2206.
  8. Andersson, C.; Nayor, M.; Tsao, C.W.; Levy, D.; Vasan, R.S. Framingham Heart Study, JACC Focus Seminar, 1/8. J. Am. Coll. Cardiol. 2021, 77, 2680–2692.
  9. Stamler, J.; Naton, J.D. The Multiple Risk Factor Intervention Trial (MRFIT)—Importance then and now. JAMA 2008, 300, 1343–1345.
  10. Makin, A.J.; Chung, N.A.; Silverman, S.H.; Lip, G.Y. Vascular endothelial growth factor and tissue factor in patients with established peripheral artery disease: A link between angiogenesis and thrombogenesis? Clin. Sci. 2003, 104, 397–404.
  11. Lassila, R. Role and Management of Coagulation Disorders in Peripheral Arterial Disease. Scand. J. Surg. 2012, 101, 94–99.
  12. Olie, R.H.; van der Meijden, P.E.J.; Ten Cate, H. The coagulation system in atherothrombosis: Implications for new therapeutic strategies. Res. Pract. Thromb. Haemost. 2018, 2, 188–198.
  13. Wilcox, J.N.; Smith, K.M.; Schwartz, S.M.; Gordon, D. Localization of tissue factor in the normal vessel wall and the atherosclerotic plaque. Proc. Natl. Acad. Sci. USA 1989, 86, 2839–2843.
  14. Borissoff, J.I.; Heeneman, S.; Kilinç, E.; Kaššák, P.; Van Oerle, R.; Winckers, K.; Govers-Riemslag, J.W.; Hamulyák, K.; Hackeng, T.M.; Daemen, M.J.; et al. Early Atherosclerosis Exhibits an Enhanced Procoagulant State. Circulation 2010, 122, 821–830.
  15. Gertow, K.; Amato, M.; Werba, J.P.; Bianchi, E.; Parolari, A.; Colnago, D.; Brambilla, M.; Ravani, A.; Veglia, F.; Baldassarre, D.; et al. Tissue factor gene promoter haplotype associates with carotid intima-media thickness in subjects in cardiovascular risk prevention. Atherosclerosis 2009, 207, 168–173.
  16. Westmuckett, A.D.; Lupu, C.; Goulding, D.A.; Das, S.; Kakkar, V.V.; Lupu, F. In situ analysis of tissue factor-dependent thrombin generation in human atherosclerotic vessels. Thromb. Haemost. 2000, 84, 904–911.
  17. Narula, N.; Dannenberg, A.J.; Olin, J.W.; Bhatt, D.L.; Johnson, K.W.; Nadkarni, G.; Min, J.; Torii, S.; Poojary, P.; Anand, S.S.; et al. Pathology of Peripheral Artery Disease in Patients with Critical Limb Ischemia. J. Am. Coll. Cardiol. 2018, 72, 18.
  18. Kockx, M.M.; De Meyer, G.R.; Muhring, J.; Bult, H.; Bultinck, J.; Herman, A.G. Distribution of cell replication and apoptosis in atherosclerotic plaques of cholesterol-fed rabbits. Atherosclerosis 1996, 120, 115–124.
  19. Shah, P.K.; Falk, E.; Badimon, J.J.; Fernandez-Ortiz, A.; Mailhac, A.; Villareal-Levy, G.; Fallon, J.T.; Regnstrom, J.; Fuster, V. Human monocyte derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques: Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 1995, 92, 1565–1569.
  20. Hetterich, H.; Webber, N.; Willner, M.; Herzen, J.; Birnbacher, L.; Hipp, A.; Marschner, M.; Auweter, S.D.; Habbel, C.; Schüller, U.; et al. AHA classification of coronary and carotid atherosclerotic plaques by grating-based phase-contrast computed tomography. Eur. Radiol. 2016, 26, 3223–3233.
  21. Derksen, W.J.; de Vries, J.P.; Vink, A.; Velema, E.; Vos, J.A.; de Kleijn, D.; Moll, F.L.; Pasterkamp, G. Histologic atherosclerotic plaque characteristics are associated with restenosis rates after endarterectomy of the common and superficial femoral arteries. J. Vasc. Surg. 2010, 52, 592–599.
  22. Ross, R.; Wight, T.N.; Strandness, E.; Thiele, B. Human atherosclerosis. I. Cell constitution and characteristics of advanced lesions of the superficial femoral artery. Am. J. Pathol. 1984, 114, 79–93.
  23. McDermott, M.M.; Kramer, C.M.; Tian, L.; Carr, J.; Guralnik, J.M.; Polonsky, T.; Carroll, T.; Kibbe, M.; Criqui, M.H.; Ferrucci, L.; et al. Plaque Composition in the Proximal Superficial Femoral Artery and Peripheral Artery Disease Events. J. Am. Coll. Cardiol. Cardiovasc. Imaging 2017, 10, 1003–1012.
  24. Abbas, A.E.; Zacharias, S.K.; Goldstein, J.A.; Hanson, I.D.; Safian, R.D. Invasive characterization of atherosclerotic plaque in patients with peripheral arterial disease using near-infrared spectroscopy intravascular ultrasound. Catheter. Cardiovasc. Interv. 2017, 90, 461–470.
  25. Polonsky, T.S.; Liu, K.; Tian, L.; Carr, J.; Carroll, T.J.; Berry, J.; Criqui, M.H.; Ferrucci, L.; Guralnik, J.M.; Kibbe, M.R.; et al. High-Risk Plaque in the Superficial Femoral Artery of People with Peripheral Artery Disease: Prevalence and Associated Clinical Characteristics. Atherosclerosis 2014, 237, 169–176.
  26. Jezovnik, M.K.; Zidar, N.; Lezaic, L.; Gersak, B.; Poredos, P. Identification of inflamed atherosclerotic lesions in vivo using PET-CT. Inflammation 2014, 37, 426–434.
  27. Rudd, J.H.; Myers, K.S.; Bansilal, S.; Machac, J.; Woodward, M.; Fuster, V.; Farkouh, M.E.; Fayad, Z.A. Relationships among regional arterial inflammation, calcification, risk factors, and biomarkers: A prospective fluorodeoxyglucose positron-emission tomography/computed tomography imaging study. Circ. Cardiovasc. Imaging 2009, 2, 107–115.
  28. Fischer, A.; Gutstein, D.E.; Fuster, V. Thrombosis and coagulation abnormalities in the acute coronary syndromes. Cardiol. Clin. 1999, 17, 283–294.
  29. Marynenko, T.; Halenova, T.; Raksha, N.; Vovk, T.; Tyravska, Y.; Savchuk, O.; Ostapchenko, L. Coagulation markers in patients with coronary artery disease. J. Biol. Res. 2022, 95, 10259.
  30. Sarnak, M.J.; Levey, A.S.; Schoolwerth, A.C.; Coresh, J.; Culleton, B.; Hamm, L.L.; McCullough, P.A.; Kasiske, B.L.; Kelepouris, E.; Klag, M.J.; et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003, 108, 2154–2169.
  31. O’Hare, A.; Johansen, K. Lower-extremity peripheral arterial disease among patients with end-stage renal disease. J. Am. Soc. Nephrol. 2001, 12, 2838–2847.
  32. Roumeliotis, S.; Mallamaci, F.; Zoccal, C. Endothelial Dysfunction in Chronic Kidney Disease, from Biology to Clinical Outcomes: A 2020 Update. J. Clin. Med. 2020, 9, 2359.
  33. Wattanakit, K.; Folsom, A.R.; Selvin, E.; Coresh, J.; Hirsch, A.T.; Weatherley, B.D. Kidney function and risk of peripheral arterial disease: Results from the Atherosclerosis Risk in Communities (ARIC) Study. J. Am. Soc. Nephrol. 2007, 18, 629–636.
  34. O’Hare, A.M.; Hsu, C.Y.; Bacchetti, P.; Johansen, K.L. Peripheral vascular disease risk factors among patients undergoing hemodialysis. J. Am. Soc. Nephrol. 2002, 13, 497–503.
  35. Jaar, B.G.; Plantinga, L.C.; Astor, B.C.; Fink, N.E.; Longenecker, C.; Tracy, R.P.; Marcovina, S.M.; Powe, N.R.; Coresh, J. Novel and traditional cardiovascular risk factors for peripheral arterial disease in incident-dialysis patients. Adv. Chronic. Kidney. Dis. 2007, 14, 304–313.
  36. Gimbrone, M.A.; García-Cardeña, G. Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis. Circ. Res. 2016, 118, 620–636.
  37. Düsing, P.; Zietzer, A.; Goody, P.R.; Hosen, M.R.; Kurts, C.; Nickenig, G.; Jansen, F. Vascular pathologies in chronic kidney disease: Pathophysiological mechanisms and novel therapeutic approaches. J. Mol. Med. 2021, 99, 335–348.
  38. Stenvinkel, A.; Alvestrand, A. Inflammation in end-stage renal disease: Sources, consequences and therapy. Semin. Dial 2022, 15, 330–338.
  39. Stenvinkel, P. Endothelial dysfunction and inflammation—is there a link? Nephrol. Dial Transpl. 2001, 16, 1968–1971.
  40. Igari, K.; Kudo, T.; Toyofuku, T.; Inoue, Y. The relationship between endothelial dysfunction and endothelial cell markers in peripheral arterial disease. PLoS ONE 2016, 11, e0166840.
  41. Cuenca, M.V.; Van Bezu, J.; Beelen, R.H.J.; Vervloet, M.G.; Hordijk, P.L. Stabilization of cell-Cell junctions by active Vitamin D ameliorates uraemia-Induced loss of human endothelial barrier function. Nephrol. Dial. Transplant. 2019, 34, 252–264.
  42. Himmelfarb, J.; Stenvinkel, P.; Ikizler, T.A.; Hakim, R.M. The elephant of uremia: Oxidative stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2022, 62, 1524–1538.
  43. Annuk, M.; Zilmer, M.; Lind, L.; Linde, T.; Fellström, B. Oxidative stress and endothelial function in chronic renal failure. J. Am. Soc. Nephrol. 2001, 12, 2747–2752.
  44. Yilmaz, M.I.M.I.; Saglam, M.; Caglar, K.; Cakir, E.; Sonmez, A.; Ozgurtas, T.; Aydin, A.; Eyileten, T.; Ozcan, O.; Acikel, C.; et al. The determinants of endothelial dysfunction in CKD: Oxidative stress and asymmetric dimethylarginine. Am. J. Kidney Dis. 2006, 47, 42–50.
  45. Yilmaz, M.I.; Sonmez, A.; Karaman, M.; Ay, S.A.; Saglam, M.; Yaman, H.; Kilic, S.; Eyileten, T.; Caglar, K.; Oguz, Y.; et al. Low triiodothyronine alters flow-Mediated vasodilatation in advanced nondiabetic kidney disease. Am. J. Nephrol. 2011, 33, 25–32.
  46. Shuto, E.; Taketani, Y.; Tanaka, R.; Harada, N.; Isshiki, M.; Sato, M.; Nashiki, K.; Amo, K.; Yamamoto, H.; Higashi, Y.; et al. Dietary phosphorus acutely impairs endothelial function. J. Am. Soc. Nephrol. 2009, 20, 1504–1512.
  47. Vervloet, M. Renal and extrarenal effects of fibroblast growth factor 23. Nat. Rev. Nephrol. 2019, 15, 109–120.
  48. Silswal, N.; Touchberry, C.D.; Daniel, D.R.; McCarthy, D.L.; Zhang, S.; Andresen, J.; Stubbs, J.R.; Wacker, M.J. FGF23 directly impairs endothelium-Dependent vasorelaxation by increasing superoxide levels and reducing nitric oxide bioavailability. Am. J. Physiol. Endocrinol. Metab. 2014, 307, E426–E436.
  49. Baylis, C. Arginine, arginine analogs and nitric oxide production in chronic kidney disease. Nat. Clin. Pract. Nephrol. 2006, 2, 209–220.
  50. Batkoa, K.; Krzanowskia, M.; Gajdab, M. Endothelial injury is closely related to osteopontin and TNF receptormediated inflammation in end-stage renal disease. Cytokine 2019, 121, 54729.
  51. Yoshii, Y.; Okada, Y.; Sasaki, S.; Mori, H.; Oida, K.; Ishii, H. Expression of thrombomodulin in human aortic smooth muscle cells with special reference to atherosclerotic lesion types and age differences. Med. Electron. Microsc. 2003, 36, 165–172.
  52. Ishii, H.; Uchiyama, H.; Kazama, M. Soluble thrombomodulin antigen in conditioned medium is increased by damage of endothelial cells. Thromb. Haemost. 1991, 65, 618–623.
  53. Pircher, J.; Merkle, M.; Wörnle, M.; Ribeiro, A.; Czermak, T.; Stampnik, Y.; Mannell, H.; Niemeyer, M.; Vielhauer, V.; Krötz, F. Prothrombotic effects of tumor necrosis factor alpha in vivo are amplified by the absence of TNF-alpha receptor subtype 1 and require TNF-alpha receptor subtype 2. Arthritis Res. Ther. 2012, 14, R225.
  54. El-Abbadi, M.M.; Pai, A.S.; Leaf, E.M.; Yang, H.Y.; Bartley, B.A.; Quan, K.K.; Ingalls, C.M.; Liao, H.W.; Giachelli, C.M. Phosphate feeding induces arterial medial calcification in uremic mice: Role of serum phosphorus, fibroblast growth factor-23, and osteopontin. Kidney Int. 2009, 75, 1297–1307.
  55. Pedersen, T.X.; Madsen, M.; Junker, N.; Christoffersen, C.; Vikeså, J.; Bro, S.; Hultgårdh-Nilsson, A.; Nielsen, L.B. Osteopontin deficiency dampens the pro-atherogenic effect of uraemia. Cardiovasc. Res. 2013, 98, 352–359.
  56. Barreto, D.V.; Lenglet, A.; Liabeuf, S.; Kretschmer, A.; Barreto, F.C.; Nollet, A.; Slama, M.; Choukroun, G.; Brazier, M.; Massy, Z. Prognostic implication of plasma osteopontin levels in patients with chronic kidney disease. Nephron. Clin. Pract. 2011, 117, c363–c372.
  57. van der Vorm, L.N.; Visser, R.; Huskens, D.; Veninga, A.; Adams, D.L.; Remijn, J.A.; Hemker, H.C.; Rensma, P.L.; van Horssen, R.; de Laat, B. Circulating active von Willebrand factor levels are increased in chronic kidney disease and end-Stage renal disease. Clin. Kidney J. 2020, 13, 72–74.
  58. Péquériaux, N.C.; Fijnheer, R.; Gemen, E.F.; Barendrecht, A.D.; Dekker, F.W.; Krediet, R.T.; Beutler, J.J.; Boeschoten, E.W.; Roest, M. Plasma concentration of von Willebrand factor predicts mortality in patients on chronic renal replacement therapy. Nephrol. Dial. Transplant. 2012, 27, 2452–2457.
  59. Nascimento, M.-M.; Pecoits-Filho, R.; Lindholm, B. Inflammation, Malnutrition and Atherosclerosis in End-Stage Renal Disease: A Global Perspective. Blood Purif. 2002, 20, 454–458.
  60. Hirsch, A.T.; Hartman, L.; Town, R.J.; Virnig, B.A. National health care costs of peripheral arterial disease in the Medicare population. Vasc. Med. 2008, 13, 209–215.
  61. Matsushita, K.; Ballew, S.H.; Coresh, J.; Arima, H.; Ärnlöv, J.; Cirillo, M.; Ebert, N.; Hiramoto, J.S.; Kimm, H.; Shlipak, M.G.; et al. Article measures of chronic kidney disease and risk of incident peripheral artery disease: A collaborative meta-analysis of individual partecipant data. Lancet Diabetes Endocrinol. 2017, 5, 718–728.
  62. Bourrier, M.; Ferguson, T.W.; Embil, J.M.; Rigatto, C.; Komenda, P.; Tangri, N. Peripheral artery disease: Its adverse consequences with and without CKD. Am. J. Kidney Dis. 2020, 75, 705–712.
  63. Gilhotra, R.A.; Rodrigues, B.T.; Vangaveti, V.N.; Kan, G.; Porter, D.; Sangla, K.S.; Malabu, U.H. Non-traumatic lower limb amputation in patients with end-stage renal failure on dialysis: An Australian perspective. Ren. Fail. 2016, 38, 1036–1043.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
Video Production Service
Feedback